Canada's Endoceutics has filed the paperwork on an IPO designed to raise $75 million. Researchers at the company have been developing therapies for endocrine-related disorders in postmenopausal women and aging men as well as a hormone therapy for preventing breast cancer. Endoceutics has plans to launch three late-stage trials in the next year. The money will be used to advance two of its therapies to planned NDAs in 2008 and 2009. Analysts noted that the company reported only two full time workers on the payroll, with two more on contract.
- read the Wall Street 24/7 report